Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells
Open Access
- 28 August 2009
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 158 (2) , 588-600
Abstract
Background and purpose: Early detection of resistance development is crucial for imatinib‐based treatment in chronic myeloid leukaemia (CML) patients. We aimed to distinguish metabolic markers of cell resistance to imatinib.Experimental approach: Two human imatinib‐sensitive CML cell lines: LAMA84‐s and K562‐s, and their resistant counterparts: LAMA84‐r and K562‐r (both resistant to 1 µM imatinib), and K562‐R (5 µM) were analysed by nuclear magnetic resonance spectroscopy to assess global metabolic profiling, including energy state, glucose and phospholipid metabolism.Key results: We found, by Western blotting and flow cytometry, that the levels of Bcr‐Abl tyrosine kinase and multi‐drug resistance p‐glycoprotein were inconsistent among resistant clones. On the other hand, phospholipid metabolism and lactate production were highly predictive for cell response to imatinib. As previously reported, sensitive cells showed significantly decreased glycolytic activity (lactate) and phospholipid synthesis (phosphocholine) as well as increased phospholipid catabolism (glycerophosphocholine) after 24 h of 1 µM imatinib treatment, which correlated with inhibition of cell proliferation and induction of apoptosis. In contrast to their sensitive counterparts, the K562‐r, K562‐R and LAMA84‐r maintained increased phospholipid synthesis and glycolytic lactate production in the presence of 1 µM (K562‐r and LAMA84‐r) and 5 µM (K562‐R) imatinib.Conclusions and implications: Specific metabolic markers for early detection of imatinib resistance, including increased glycolytic activity and phospholipid turnover, can be identified in resistant clones. Once validated in human isolated leukocytes, they may be used to monitor the responsiveness of CML patients to treatment.Keywords
This publication has 42 references indexed in Scilit:
- Development and validation of a sensitive assay for the quantification of imatinib using LC/LC‐MS/MS in human whole blood and cell cultureBiomedical Chromatography, 2009
- Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cellsBlood, 2008
- Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylateBlood, 2006
- Resistance to imatinib, low-grade FDG-avidity on PET, and acquired KIT exon 17 mutation in gastrointestinal stromal tumourThe Lancet Oncology, 2005
- Regulation of glial metabolism studied by 13C‐NMRNMR in Biomedicine, 2003
- Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatmentBlood, 2002
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 2001
- Inhibition of the ABL Kinase Activity Blocks the Proliferation of BCR/ABL+Leukemic Cells and Induces ApoptosisBlood Cells, Molecules, and Diseases, 1997
- Information from combined 1H and 31P NMR studies of cell extracts: Differences in metabolism between drug-sensitive and drug-resistant MCF-7 human breast cancer cellsBiochemical and Biophysical Research Communications, 1990
- On the Origin of Cancer CellsScience, 1956